No Data
No Data
Stocks with potential seen from the volume change, such as BS.
Stock code <2242>MXS Dow Inc 573.7 4.3 volume* <6176 ̄Branchista 592 73 382600* <194A ̄Wolves 944 83 166600* <2735 ̄Watts 752 25 314000* <3321 ̄Mitachi 1143 46 56200* <3623 ̄BS 1709
OTS - Resurgence, WOLVES HAND, which has a collaborative research contract, has started clinical trials at the Veterinary Advanced Medical Research Institute.
Rebound. After the end of trading on the 23rd, WOLVES HAND, a consolidated subsidiary, announced that it has signed a joint research contract with Cancer Precision Medicine in the veterinary field for early detection of cancer by liquid biopsy, and has started clinical trials at the Veterinary Advanced Medical Research Institute, which is considered to be positive news. In the future, it aims to sample cfDNA in the plasma of dogs and cats over time for early cancer detection by liquid biopsy.
Volume change rate ranking (13:00) - Chukyo Pharmaceuticals, Kawamoto Industries, etc. ranked in.
In the volume change rate ranking, you can understand the interests of market participants, such as the trend of speculation, by comparing the average volume of the past 5 days with the volume on the delivery day. Top volume change rate [As of August 26, 13:32] (comparison of average volume of the past 5 days)] Code => Stocks => Volume => 5-day average volume => Volume change rate => Stock price change rate <9708> Imperial Hotel 366,300 33,248.48 258.00% 0.0659% <135A>
Emerging markets digest: IPS continues to soar significantly, while IBIS hit the daily limit.
<194A> WOLVES 818 fell by 58. In the June 24th year, the revenue was 4.99 billion yen (+7.3% YoY), operating profit was 0.827 billion yen (+3.0% YoY), ordinary profit was 0.8 billion yen (+0% YoY). In the future, we will expand our business with both the establishment of our own hospitals and business succession/M&A, strengthen the research and development of drugs and commodities related to animal medicine by utilizing the clinical base that the group possesses, and promote the creation of new sources of revenue in animal medicine beyond clinical practice.
WOLVES - announced a mixed but strong financial report for the June 2024 period.
Fallen. In June 24, the sales revenue for the period was 4.99 billion yen (+7.3% from the previous period), the operating profit was 0.827 billion yen (+3.0% from the previous period), and the ordinary profit was 0.8 billion yen (same as previous period). In the future, the company will expand its business scale through the establishment of its own hospitals and both business succession and M&A, and will strengthen research and development activities for drugs and commodities related to animal medicine, leveraging the clinical foundation owned by the group, and promote the creation of new sources of revenue other than clinical practices in animal medicine. For the period of June in 5 years, the ordinary profit is also expected to be higher than the previous period.
Wolves Hand: Supplementary explanatory materials for the financial results announcement of June 2024.
No Data